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Abstract
Background: Glaesserella parasuis, the causative agent of Glӓsser’s disease, is widespread in swine globally resulting
in significant economic losses to the swine industry. Prevention of Glӓsser’s disease in pigs has been plagued with
an inability to design broadly protective vaccines, as many bacterin based platforms generate serovar or strain
specific immunity. Subunit vaccines are of interest to provide protective immunity to multiple strains of G. parasuis.
Selected proteins for subunit vaccination should be widespread, highly conserved, and surface exposed.
Results: Two candidate proteins for subunit vaccination (RlpB and VacJ) against G. parasuis were identified using
random mutagenesis and an in vitro organ culture system. Pigs were vaccinated with recombinant RlpB and VacJ,
outer membrane proteins with important contributions to cellular function and viability. Though high antibody
titers to the recombinant proteins and increased interferon-γ producing cells were found in subunit vaccinated
animals, the pigs were not protected from developing systemic disease.
Conclusions: It appears there may be insufficient RlpB and VacJ exposed on the bacterial surface for antibody to
bind, preventing high RlpB and VacJ specific antibody titers from protecting animals from G. parasuis. Additionally,
this work confirms the importance of utilizing the natural host species when assessing the efficacy of vaccine
candidates.
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Background
Glaesserella parasuis is a Gram-negative bacterial mem-
ber of the Pasteurellaceae family and the causative agent
of Glässer’s disease, which is characterized by a fibrinous
polyserositis, meningitis, and arthritis. G. parasuis can
cause high morbidity and mortality in herds resulting in
significant losses to the swine industry annually [1].
There are 15 identified serovars of G. parasuis; however,
many isolates are untypable [2]. Multiple serovars can
circulate within a herd, although it appears some sero-
vars are more capable of causing systemic disease [3, 4].
To prevent G. parasuis disease in the swine industry,
efforts have focused on developing broadly protective
vaccines. Commercially available G. parasuis vaccines
are predominantly based on a bacterin platform. Bac-
terins have been shown to provide good homologous
protection [5–7]; however, this protection can be serovar
or strain specific [7–10], leaving swine susceptible to dis-
ease with other serovars or strains in the field. Currently,
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no available vaccine is able to provide broad cross pro-
tection for G. parasuis. This may be due in part to the
bacterial capsule, which is serovar specific and functions
to mask other antigens on the bacterial surface that may
contribute to the protective immune response [11, 12].
The importance of a vaccine conferring heterologous pro-
tection has led to the pursuit of alternative vaccine plat-
forms that avoid the generation of capsule directed
immunity, such as protein and peptide vaccines. Antigens
targeted for G. parasuis protein and peptide vaccines
should be highly conserved and widespread amongst iso-
lates and found on the surface of the bacterium.
Several mechanisms have been employed to identify
subunit vaccine candidates, including the use of hyper-
immune or post-challenge serum from pigs to identify
proteins separated by gel electrophoresis and in silico
prediction methods [13–15]. In this report, we utilized a
previously reported functional genomic screen to iden-
tify subunit vaccine candidates [16]. This screen identi-
fies proteins associated with bacterial fitness and
resulted in the selection of RlpB and VacJ as vaccine
candidates. The rlpB gene (lptE) is best studied in
Escherichia coli. RlpB is a low abundance outer mem-
brane lipoprotein that functions in outer membrane as-
sembly, specifically in mobilizing lipopolysaccharide to
the outer membrane’s outer surface, and plays an essen-
tial role in cellular viability [17–19]. The vacJ gene has
been assessed in G. parasuis previously [20]. VacJ is an
outer membrane lipoprotein that contributes to outer
membrane integrity [20]. It has also been associated with
stress tolerance, serum resistance, and host cell inter-
action in G. parasuis and other Gram negative patho-
gens [20–23]. Additionally, the vacJ gene was previously
assessed for potential as a subunit vaccine against G. para-
suis in a guinea pig model of disease [15]. In order to as-
sess antigenicity and the potential of recombinant RlpB
and VacJ (rRlpB and rVacJ) to stimulate a protective im-
mune response in swine, we vaccinated and boosted naïve
pigs with rRlpB and rVacJ 3 weeks apart. Their antibody
response was quantified and protection was evaluated
through challenge with the G. parasuis strain HS069.
Results
Comparison of RlpB and VacJ sequence identity
RlpB and VacJ amino acid sequences were compared to
evaluate protein sequence diversity among G. parasuis
isolates. The genome sequence was obtained for 11G.
parasuis strains representing 9 different serovars and
amino acid sequences of RlpB and VacJ were generated.
The rlpB gene was obtained for 9 of the 11 strains, the
SW114 and 174 genomes are both draft sequences that
contain gaps and no rlpB was identified. The RlpB
amino acid sequence for the remaining 9 strains showed
an identity greater than 96% among all strains. A
complete vacJ gene was present in 9 of the 11 strains.
The vacJ gene was positioned near the end of a contig in
MN-H and was absent from SW140, which may be asso-
ciated with gaps in the genome of these strains. Amino
acid identity among the other 9 strains revealed high
conservation, with a 98% or higher identity between
isolates.
Antibody response to vaccination
Antibody titers (IgG) were determined by ELISA for
rRlpB and rVacJ. Minimal reactivity was seen in animals
prior to vaccination. Modest increases in IgG titer to
rRlpB and rVacJ were seen in the control and bacterin
vaccinated groups prior to challenge, while significant
increases in titer with a memory response were seen to
both rRlpB and rVacJ for the subunit vaccinated pigs
(Fig. 1a and b). Additionally, animals were screened for
antibody response to G. parasuis HS069. There was
an increase in titer for bacterin vaccinated animals,
but no change in titer for subunit vaccinated or con-
trol animals (Fig. 1c). Titers for bacterin vaccinated
animals were significantly higher at day 21 (p = 0.03)
and day 42 (p < 0.01) than that of subunit vaccinated
and control animals.
Western blotting was utilized to evaluate the specifi-
city of the antibody response. Reactivity to G. parasuis
HS069 whole cell sonicate was not seen at 25 kDa or 35
kDa, which would correlate to intact RlpB and VacJ re-
spectively (Fig. 2a); however, some reactivity was noted
at lower molecular weights. Probing with serum from
the bacterin vaccinated animals revealed no reactivity to
the recombinant proteins (Fig. 2b).
Cell mediated immune response
Peripheral blood mononuclear cells (PBMCs) were col-
lected at the time of boost (day 21), 1 week after boost
(day 28), and at challenge (day 42) to evaluate the preva-
lence of interferon-γ (IFN-γ) secreting cells. Animals im-
munized with the subunit vaccine were found to have
more IFN-γ producing cells showing reactivity to pooled
rRlpB and rVacJ than control animals and bacterin vac-
cinated animals on day 21 (p = 0.014 and 0.006, respect-
ively), but differences did not reach the statistical
threshold on day 28 and 42 (Fig. 3). Additionally, more
IFN-γ producing PBMCs were noted in the subunit vac-
cine group on day 21 than day 28 or 42, although this
was not statistically significant. Minimal reactivity
was seen in both the control animals and subunit
vaccinated animals to stimulation with heat killed G.
parasuis HS069, significantly less than that seen in
HS069 bacterin vaccinated animals on day 21 and 28
(p < 0.01) (Fig. 3).
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Evaluation of protection from G. parasuis challenge
Challenge with G. parasuis HS069 caused severe clin-
ical signs (neurologic signs or severe depression)
which were exhibited by 5/6 control pigs leading to
euthanasia on days 2–5 after challenge (Fig. 4). G.
parasuis was isolated from at least one site [serosal
surface, joint fluid, cerebrospinal fluid (CSF),
bronchoalveolar lavage fluid (BALF)] in all five clinic-
ally ill control animals. One control pig survived until
the end of the study period (day 12 post-challenge)
and G. parasuis was not isolated from any site sam-
ples collected at the time of necropsy.
Four of the six subunit vaccinated pigs also exhibited
severe clinical signs and were euthanized on days 2–5
a
b
c
Fig. 1 ELISA titers against rRlpB (a), rVacJ (b), and HS069 (c). A significantly higher titer to rRlpB and rVacJ was noted for pigs vaccinated with the
G. parasuis recombinant proteins than the control animals or the bacterin vaccinated animals. Higher titers to HS069 were seen in HS069 bacterin
vaccinated animals. No difference in titer to HS069 was noted between control animals and subunit vaccinated animals
Fig. 2 Western blot evaluating antibody specificity. SDS-PAGE of rRlpB (lane 2), rVacJ (lane 3), and G. parasuis HS069 sonicate (lane 4) transferred
to a PVDF membrane and probed with sera from rRlpB and rVacJ vaccinated pigs (a) or bacterin vaccinated pigs (b). No reactivity was noted to
proteins sized that of RlpB (approximately 25 kDa) or VacJ (approximately 35 kDa) in H. parasuis HS069 sonicate when probed with pooled sera
from the subunit vaccinated animals. Additionally, no reactivity was noted to rRlpB or rVacJ when probed with pooled sera from bacterin
vaccinated animals
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after challenge (Fig. 4). G. parasuis was isolated from at
least one site in all four of the clinically ill animals. Two
subunit vaccinated pigs exhibited no clinical signs during
the study period and were culture negative for G. para-
suis from site samples at necropsy. No difference in sur-
vival time was noted between the control animals and
those vaccinated with the subunit vaccine (P = 0.53).
Bacterin vaccinated pigs showed significantly better
protection than control or subunit vaccinated pigs (P <
0.01 and P = 0.02, respectively). All six bacterin vacci-
nated pigs survived until the end of the challenge period
and exhibited no clinical signs of G. parasuis disease
(Fig. 4). At necropsy, G. parasuis was isolated in the
BALF of 3/6 pigs, but no G. parasuis was cultured in the
serosal swab, joint fluid, or CSF of any of the bacterin
vaccinated animals.
Discussion
G. parasuis vaccine development has suffered from diffi-
culty generating a broadly cross-protective vaccine.
Many platforms have been attempted: whole cell bac-
terins, outer-membrane vesicles, live avirulent strains,
and a variety of subunit vaccines [5, 6, 13, 15, 24–27].
While homologous protection with whole cell vaccines
is often high, those studies investigating heterologous
protection show less efficacy [7–10]. This is thought to
Fig. 3 IFN-γ secreting cells responding to stimulation with heat killed G. parasuis HS069 and pooled rRlpB and rVacJ. More IFN-γ secreting cells
responsive to pooled rRlpB and rVacJ were seen in the subunit vaccinated animals than the control animals (p = 0.014) and bacterin vaccinated
animals (p = 0.006) on day 21 (open shapes). Differences did not meet the statistical threshold on day 28 or 42. Minimal IFN-γ secreting cells were
seen in the subunit vaccinated or the control animals in response to stimulation with heat killed G. parasuis HS069 (filled shapes). Bacterin
vaccinated animals had significantly more IFN-γ secreting cells than subunit vaccinated or control animals at day 21 and 28 (p < 0.01)
Fig. 4 Survival of animals post challenge. Bacterin vaccinated pigs showed significantly better survival post-homologous challenge than the
control animals or the G. parasuis protein antigen vaccinated animals. No difference was noted between the control pigs and G. parasuis protein
antigen vaccinated pigs in survival post-challenge
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be associated with the serovar or strain specific response
of capsular polysaccharide and some protein antigens.
Protein subunit vaccines have good potential to generate
a broadly protective immune response if the antigen is
widespread, highly conserved, and exposed on the sur-
face of the bacterium or secreted. In this study, we de-
termined two outer membrane proteins, RlpB and VacJ,
as subunit vaccine candidates and assessed the capacity
of these proteins to protect against G. parasuis disease
in pigs.
RlpB and VacJ are outer membrane proteins with im-
portant contributions to cellular function, including
membrane stability and resistance to stressors such as
complement [18, 20, 21]. Here, we found RlpB and VacJ
play a role in colonization of an in vitro organ culture
(IVOC) of swine respiratory epithelium and are highly
conserved in isolates of G. parasuis of different serovars,
making them good subunit vaccine candidates. Add-
itionally, VacJ has previously been utilized in a guinea
pig model of G. parasuis disease and found to confer
good protection [15]. RlpB and VacJ were expressed as
recombinant proteins, purified, and used to vaccinate
cesarean derived, colostrum deprived (CDCD) pigs. We
found the proteins to be highly immunogenic and cap-
able of stimulating a high antibody titer and an anam-
nestic antibody response following a second vaccination
(Fig. 1). We also detected cellular response to the re-
combinant proteins through detection of IFN-γ secreting
PBMCs (Fig. 3). This response was highest at 21 days
post vaccination and declined after boost vaccination,
consistent with previous reports of protein specific IFN-
γ producing cells [16]. Although response to subunit
vaccination was noted in both antibody titer and reactive
PBMCs, it was unable to protect vaccinated animals
from challenge with the homologous G. parasuis strain
(Fig. 4).
To better understand the lack of protection seen after
subunit vaccination, we evaluated the reactivity of anti-
sera generated from subunit vaccination and bacterin
vaccination. Western blotting revealed no reactivity be-
tween pooled anti-sera from subunit vaccinated pigs and
whole cell sonicate at the 25 kDa and 35 kDa sizes con-
sistent with RlpB and VacJ; however, reactivity was seen
at low molecular weights, which may indicate protein
degradation in the sonicate (Fig. 2a). There was also no
reactivity between pooled anti-sera from bacterin vacci-
nated pigs and rRlpB and rVacJ (Fig. 2b). We suspect
the absence of reactivity is associated with limited ex-
pression of RlpB and VacJ by G. parasuis HS069, which
is consistent with previous reports in E. coli for RlpB
[17], or associated with minimal exposure of these lipo-
proteins at the bacterial surface. Low expression or min-
imal exposure of RlpB and VacJ in vivo would also
prevent high antibody titers to these proteins from
providing protection to challenged pigs. Additionally,
the recombinant proteins used for vaccination in this
study were isolated under denaturing conditions and
refolded, which may have altered the presentation of
some antigens.
Although this study included small animal numbers in
each group (n = 6), group size was sufficient to see dif-
ferences in protection and immune reactivity between
bacterin vaccinated animals and subunit vaccinated ani-
mals. Additionally, the animals included in this study
were crossbred with an unknown genetic background
which may increase within group variation; however, this
is consistent with production settings.
Conclusions
Here, we found vaccination of pigs with rRlpB and rVacJ
was not capable of inducing a protective immune re-
sponse, making rRlpB and rVacJ unsuitable for a subunit
vaccine to combat G. parasuis disease. Further, this re-
port confirms the importance of testing vaccine efficacy
in the natural host species. Rodent models for G. para-
suis do not adequately represent disease in the natural
host, as rodents do not develop the typical signs of G.
parasuis and challenge requires inoculation via an artifi-
cial route, typically intraperitoneal or intravenous. These
factors make rodent models a starting point for screen-
ing subunit vaccine components for G. parasuis, but the
translation to swine is not exact and further testing in
pigs is required.
Methods
Bacterial isolates and growth conditions
Transposon mutagenesis and cloning was done with the
G. parasuis serovar 5 isolate 29755, a virulent strain iso-
lated from the lung of a pig diagnosed with polyserositis
[28, 29]. G. parasuis HS069, a virulent serovar 5 isolate
from the lungs of a pig with respiratory disease caused
by G. parasuis [30], was utilized for bacterin production
and challenge. G. parasuis was grown using brain heart
infusion base (BHI) (BD Biosciences, San Jose, CA) sup-
plemented with 10% heat-inactivated horse serum and
0.1 mg/mL nicotinamide adenine dinucleotide (NAD).
Bacto agar (BD Biosciences) was added to generate solid
media.
Escherichia coli strains were grown on Luria-Bertani
(LB) agar or in LB broth (Thermo Fisher Scientific, Wal-
tham, MA). For expression, E. coli was grown in 2YT
broth (Life Technologies, Carlsbad, CA). Transformants
were selected using 100 μg/mL kanamycin (Sigma-Al-
drich, St. Louis, MO).
Selection of candidate proteins
Selection of candidate proteins was accomplished
through a previously utilized protocol combining
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functional genomic screening using a TraDIS library
generated in G. parasuis 29755 and in silico bioinfor-
matics to detect outer membrane proteins important to
bacterial fitness in a swine respiratory epithelium
in vitro organ culture (IVOC) system [16]. Briefly, genes
of interest were defined by a loss of fitness in the IVOC
system coupled with a transposon insertion in that gene.
These genes were then evaluated for subcellular
localization using PSORTb (http://db.psort.org/) and
LocateP (http://www.cmbi.ru.nl/locatep-db/cgi-bin/loca-
tepdb.py) databases. Localization utilizing literature min-
ing also enabled detection of surface-associated proteins,
specifically proteins known to be cell wall anchored or
extracellular (lipid-anchored or secretory). Proteins with
transmembrane domains in the middle of the coding se-
quence were excluded. Coding sequences of genes of
interest were compared utilizing 11G. parasuis genomes
to determine cross protection potential, as previously de-
scribed [16]. The screening resulted in the selection of
two genes of interest, rlpB and vacJ, which had not been
previously published, patented, or assessed for protec-
tion against G. parasuis in swine.
Evaluation of VacJ and RlpB sequence identity
The amino acid sequences of RlpB and VacJ were com-
pared using Geneious 9.0.5 (Biomatters Ltd., Auckland,
New Zealand). Sequences were obtained for 11 G.
parasuis strains representing 9 serovars from National
Center for Biotechnology Information (NCBI) for
SH0165 (CP001321), Nagasaki (APBT00000000),
SW114 (APBU00000000), MN-H (APBV0000000), 12,
939 (APBW00000000), 29,755 (ABKM00000000), 84–
15,995 (APBX00000000), H465 (APBY00000000), D74
(ABPZ00000000), 174 (APCA00000000), and SW140
(APCB00000000). The rlpB and vacJ genes were ex-
tracted from the genomes, translated, and compared
using a multiple sequence alignment.
Cloning and production of rVacJ and rRlpB
The DNA encoding the lipoproteins rplB and vacJ with-
out the putative secretion sequence (rplB16–164aa and
vacJ19–248aa) was amplified from G. parasuis 29755 with
the primer pairs listed in Table 1. The amplified PCR
products were cloned into the pET-30Ek/LIC expression
vector (Millipore Sigma, Burlington, MA) according to
the manufacturers’ protocols. The plasmid constructs
were verified by PCR and Sanger sequencing.
The constructed expression vectors were transformed
to E. coli BL21 (DE3) (Invitrogen, Carlsbad, CA) for ex-
pression. Fresh 2YT media (1–6 L) was inoculated with
overnight growth of E. coli BL21 (DE3) and grown to an
OD595 of 0.6. Expression was induced with 1 mM IPTG
(Sigma-Aldrich). Protein expression was verified with
SDS-PAGE from whole cell lysates.
Proteins purification from batch cultures
Isolation and Ni-NTA of rRlpB
Cell pellets containing rRlpB were resuspended in
binding buffer (10 mM imidazole, 300 mM NaCl, 50
mM phosphate, pH 8.0) and sonicated on ice in the
presence of benzonase and r-lysozyme. Lysates were
centrifuged and the supernatant containing soluble
rlpB was loaded onto a Ni NTA His-bind Superflow
(Novagen) column in binding buffer. The column was
washed in binding buffer, followed by 20 mM imid-
azole, 300 mM NaCl, 50 mM phosphate pH 8.0 before
rlpB was eluted with 250 mM imidazole, 300 mM
NaCl, 50 mM phosphate pH 8.0.
Isolation and Ni-NTA of rVacJ
Cell pellets containing rVacJ protein as inclusion bodies
were re-suspended in BugBuster Protein Extraction Re-
agent (Millipore Sigma, Burlington, MA) in the presence
of benzonase and r-Lysozyme. After centrifugation the
pellet was re-suspended in BugBuster reagent and pel-
leted followed by four washes in dilute BugBuster re-
agent (1:10). The rVacJ containing pellet was dissolved
in binding buffer (8M urea, 0.1 M sodium phosphate
buffer, 0.01M Tris, pH 8.0) and loaded onto Ni NTA
His-bind Superflow column (Novagen). The column was
washed in binding buffer, then 8M urea in 0.1M so-
dium phosphate buffer, 0.01M Tris, pH 6.5 before elu-
tion in 8M urea in 0.1M sodium phosphate buffer, 0.01
M Tris pH 4.5.
Anion exchange of rRlpB and rVacJ under denaturing
conditions using 8 M urea and dithiotreitol (DTT)
Both the rRlpB and rVacJ containing fractions from the
Ni-NTA columns were identified using A280nm and
SDS-PAGE and then dialysed into 30mM Tris/HCl pH
8.5. Most of the rVacJ precipitated due to the removal of
the urea, while the rRlpB remained in solution. Urea,
DTT and further Tris were added to the dialysate to
produce a solution of protein in 8M Urea, 15 mM DTT,
30mM Tris pH 8.5, which was incubated for 3 h at
37 °C. The pH of the mixture was adjusted to pH 8.0 and
0.2 μM filtered immediately before loading it onto
Source Q - FPLC. Anion exchange was performed using
a 25-column volume gradient (low salt buffer: 30 mM
Table 1 Primers utilized to amplify vacJ and rlpB sequences
Primer Sequence (5′-3′)
P1 (VacJ_ForA) GACGACGACAAGATGTGTACTGCTTCTATTGATCCTGAA
P2 (VacJ_RevA) GAGGAGAAGCCCGGTCAATCAATATTTTTTAGCTGTTCTTC
P3 (RlpB_ForA) GACGACGACAAGATGTGCGGTTGGCATTTTAAAAA
P4 (RlpB_RevA) GAGGAGAAGCCCGGTTATTTCGTATTTGCTAACTCTTTTTG
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Tris pH 8.0, 8M urea, 2 mM DTT and High salt buffer:
30 mM Tris pH 8.0, 8M urea, 2 mM DTT, 0.5 M sodium
chloride). Eluted peak samples were detected using
A280nm and analysed using SDS-PAGE. Proteins were
dialysed 3 times in PBS. Overnight dialysis was followed
by dialysis in fresh PBS the next day, followed by an-
other change of PBS and a second overnight dialysis.
Samples were 0.2 μM filtered to remove any precipitated
protein. Purified proteins were submitted to the Iowa
State University Protein Facility in Ames, IA for verifica-
tion by LC-MS/MS.
Western blotting
Western blotting was used to detect reactivity of sera
from bacterin vaccinated pigs to rRlpB and rVacJ and
reactivity of sera from subunit vaccinated pigs to
whole cell sonicate from G. parasuis HS069. The re-
combinant proteins (2 μg) and G. parasuis HS069
sonicate (10 μg) were run on an SDS-PAGE gel and
transferred to a PVDF membrane using the iBlot sys-
tem (Invitrogen, Carlsbad, CA). Membranes were
blocked with 10% milk in 1x Tris buffered saline with
0.05% Tween (TTBS) and probed with 5% milk in TTBS
containing 1:100 or 1:1000 pooled serum from bacterin
vaccinated or subunit vaccinated pigs, respectively. Goat
anti-swine IgG conjugated with horse radish peroxidase
(KPL, Gaithersburg, MD) at a 1:20,000 dilution in 5% milk
in TTBS was used for antibody detection with the Pierce
ECL Plus Western Blotting Substrate (Thermo Fisher Sci-
entific, Waltham, MA).
Vaccination and challenge
All animal work was approved by the USDA-ARS Na-
tional Animal Disease Center Institutional Animal Care
and Use Committee. Eighteen healthy, four-week old
cross-bred CDCD piglets were obtained from Struve
Labs International (Manning, IA). Pigs were fed a stand-
ard finishing diet and kept under laboratory biosafety
level II agriculture (BSL2-Ag) conditions at the National
Animal Disease Center. After a one-week acclimation,
piglets were randomly divided into three treatment
groups with six pigs each: vaccinated with adjuvant only
(control), vaccinated with G. parasuis HS069 bacterin
(bacterin), and vaccinated with rRlpB and rVacJ (G.
parasuis subunit). Control pigs were vaccinated intra-
muscularly with 2 mL of a 20% Emulsigen D solution.
Bacterin vaccinated pigs were inoculated intramuscularly
with 2 mL containing 1 × 109 colony forming units
(CFU) of formalin inactivated G. parasuis HS069 in a
20% Emulsigen D solution (MVP laboratories, Omaha,
NE). G. parasuis subunit vaccinated pigs were inoculated
intramuscularly with 2mL containing 100 μg each of
rRlpB and rVacJ in a 20% Emulsigen D solution. Vacci-
nations were given twice (day 0 and 21) and pigs were
challenged intranasally with 2 mL of 7 × 108 CFU/mLG.
parasuis HS069 (1 mL per nostril) on day 42 of the
study. Animals were monitored post-challenge for signs
of systemic G. parasuis disease including lameness, leth-
argy, and neurologic signs. When systemic disease was
severe, animals were humanely euthanized. All surviving
animals were euthanized 12 days post-challenge. Ani-
mals were euthanized by the intravenous administration
of an overdose of sodium pentobarbital.
Blood samples were taken on day 0, 21, 28, and 42 in
BD Vacutainer serum separator tubes (SST) (Becton
Dickinson, Franklin Lakes, NJ). Serum was collected and
frozen at − 80 °C until ELISAs were run. Additionally,
blood was collected in BD Vacutainer cell preparation
tubes (CPT) (Becton Dickinson) with sodium citrate for
the isolation of PBMCs on day 21, 28, and 42. At nec-
ropsy, samples were collected and culture was performed
on the following samples: nasal wash, serosal swab
(pleural, pericardial, and peritoneal surfaces), joint fluid
from hock or other affected joint, CSF, BALF, and
serum.
Antibody titer analysis via ELISA
Antibody titers to rRlpB and rVacJ were determined
using an indirect ELISA. Immulon-2 plates were coated
overnight at room temperature with 100 μL of recom-
binant protein or HS069 in 100 mM carbonate-
bicarbonate buffer (pH 9.6). Recombinant proteins were
used at the following concentrations: rRlpB at 0.25 μg/
mL and rVacJ at 0.125 μg/mL. HS069 was used to coat
at a concentration of 0.5 μg protein per mL. Plates were
washed three times prior to use with 1X PBS with 0.05%
Tween 20 (PBST) and blocked for 2 h with 200 μL of 2%
bovine serum albumin (BSA) in PBST. Plates were again
washed three times with PBST and probed in duplicate
with 100 μL of serial two-fold dilutions of swine antisera
in 1% BSA in PBST for 2 h. Following three washes with
PBST, protein specific IgG was detected using 100 μL of
a 1:25,000 dilution of goat anti-swine IgG conjugated
with horse-radish peroxidase (KPL) in 1% BSA in PBST.
Plates were incubated for 1 h, washed three times with
PBST, and 100 μL of tetramethylbenzidine (TMB) sub-
strate (Life Technologies, Carlsbad, CA) was added to
each well. Plates were incubated in the dark for 5 min
and stopped with 50 μL of 2 N H2SO4. The optical dens-
ity at 450 nm (OD450) was measured with a correction at
655 nm (OD655). The resulting data was modeled using
GraphPad Prism (GraphPad Software, La Jolla, CA) as a
nonlinear function of the log10 dilution and the log
(agonist)-versus-response variable slope four-parameter
logistic model. Endpoints were interpolated by using two
times the average OD of the gnotobiotic pig serum sam-
ple as the cutoff.
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Evaluation of the cell-mediated immune response
The induction of cell-mediated immunity was evaluated
following vaccination by enzyme-linked immunosorbent
spot (ELISpot) assays. IFN-γ-secreting cells were enu-
merated after in vitro stimulation with rRlpB and rVacJ.
Blood collected in CPT was used to isolate PBMCs as
previously described [31]. IFN-γ ELISpot plates were
seeded with 2.5 × 105 PBMCs per well with duplicate
wells for each treatment. PBMCs were stimulated with
the recombinant proteins in a total volume of 0.25 mL
(0.5 μg/mL of each individual protein per well). Negative
and positive control wells were treated with medium
alone or pokeweed mitogen (0.5 μg/mL), respectively.
Approximately 18 h after stimulation, ELISpot assays
were completed following manufacturer’s recommenda-
tions (R&D Systems, Minneapolis, MN). Spots corre-
sponding to IFN-γ-secreting cells were enumerated
using an S5UV ImmunoSpot instrument and software
(Cellular Technology Ltd., Shaker Heights, OH). The
number of IFN-γ-secreting cells was calculated for each
treatment in each group using the average of the dupli-
cate wells for each pig.
Statistical analysis
Statistical analysis was completed using GraphPad Prism
7. Survival curves were generated by the product limit
method of Kaplan and Meier and compared using the
log-rank test. Log10 antibody titers were compared using
two-tailed Student’s t tests to evaluate differences be-
tween groups. Cell mediated response was analyzed
using a two-way analysis of variance (ANOVA) with
Tukey’s multiple comparison posttest. Statistical signifi-
cance was designated at P < 0.05.
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